It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Activation of thermogenic brown and beige adipocytes is considered as a strategy to improve metabolic control. Here, we identify GPR180 as a receptor regulating brown and beige adipocyte function and whole-body glucose homeostasis, whose expression in humans is associated with improved metabolic control. We demonstrate that GPR180 is not a GPCR but a component of the TGFβ signalling pathway and regulates the activity of the TGFβ receptor complex through SMAD3 phosphorylation. In addition, using genetic and pharmacological tools, we provide evidence that GPR180 is required to manifest Collagen triple helix repeat containing 1 (CTHRC1) action to regulate brown and beige adipocyte activity and glucose homeostasis. In this work, we show that CTHRC1/GPR180 signalling integrates into the TGFβ signalling as an alternative axis to fine-tune and achieve low-grade activation of the pathway to prevent pathophysiological response while contributing to control of glucose and energy metabolism.
Activation of thermogenic adipocytes is a strategy to combat metabolic diseases. Here the authors report that GPR180 is a component of TGFβ signalling that promotes thermogenic adipocyte function and mediates the metabolic effects of the adipocyte-secreted factor CTHRC1, and contributes to the regulation of glucose and energy metabolism.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 Institute of Food, Nutrition and Health, ETH Zürich, Schwerzenbach, Switzerland (GRID:grid.5801.c) (ISNI:0000 0001 2156 2780)
2 Institute of Food, Nutrition and Health, ETH Zürich, Schwerzenbach, Switzerland (GRID:grid.5801.c) (ISNI:0000 0001 2156 2780); Institute of Experimental Endocrinology, Biomedical Research Center at the Slovak Academy of Sciences, Bratislava, Slovakia (GRID:grid.424960.d); Comenius University in Bratislava, Department of Animal Physiology and Ethology, Faculty of Natural Sciences, Bratislava, Slovakia (GRID:grid.7634.6) (ISNI:0000000109409708)
3 University Hospital Balgrist, University of Zurich, Biomechanics Laboratory, Zurich, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650); Institute of Biomechanics, ETH Zurich, Zurich, Switzerland (GRID:grid.5801.c) (ISNI:0000 0001 2156 2780)
4 Institute of Experimental Endocrinology, Biomedical Research Center at the Slovak Academy of Sciences, Bratislava, Slovakia (GRID:grid.424960.d)
5 Institute of Food, Nutrition and Health, ETH Zürich, Schwerzenbach, Switzerland (GRID:grid.5801.c) (ISNI:0000 0001 2156 2780); Functional Genomics Centre Zurich, ETH Zurich/ University of Zurich, Zurich, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650)
6 Université Côte d’Azur, French National Centre for Scientific Research, Inserm, iBV, Nice, France (GRID:grid.461605.0)
7 University of Turku, Turku PET Centre, Turku, Finland (GRID:grid.1374.1) (ISNI:0000 0001 2097 1371)
8 Turku University Hospital, Department of Surgery, Turku, Finland (GRID:grid.410552.7) (ISNI:0000 0004 0628 215X)
9 Institute of Experimental Endocrinology, Biomedical Research Center at the Slovak Academy of Sciences, Bratislava, Slovakia (GRID:grid.424960.d); Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia (GRID:grid.7634.6) (ISNI:0000000109409708)
10 University of Basel, Center for Transgenic Models, Basel, Switzerland (GRID:grid.6612.3) (ISNI:0000 0004 1937 0642)
11 Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany (GRID:grid.420061.1) (ISNI:0000 0001 2171 7500)
12 Cardiometabolic Diseases Research Department, Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach an der Riss, Germany (GRID:grid.420061.1) (ISNI:0000 0001 2171 7500)